Affordable Access

Access to the full text

Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer

Authors
  • Ciappuccini, Renaud1
  • Trzepla, Géraldine2
  • Heutte, Natacha3
  • Sevin, Emmanuel4
  • Galais, Marie Pierre4
  • Bardet, Stéphane1
  • 1 Centre François Baclesse, Departments of Nuclear Medicine and Thyroid Unit, 3 Avenue Général Harris – BP 5026, Cedex 05, Caen, 14076, France , Caen (France)
  • 2 Centre Hospitalo-Universitaire, Department of Endocrinology, Caen, 14000, France , Caen (France)
  • 3 Centre François Baclesse, GRECAN EA-1772, Université de Caen-Basse Normandie, and Department of Clinical Research, Caen, 14076, France , Caen (France)
  • 4 Centre François Baclesse, Department of Oncology, Caen, 14076, France , Caen (France)
Type
Published Article
Journal
EJNMMI Research
Publisher
Springer (Biomed Central Ltd.)
Publication Date
May 07, 2012
Volume
2
Issue
1
Identifiers
DOI: 10.1186/2191-219X-2-18
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundTo assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer (DTC) treated with sorafenib.FindingsVisual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses were conducted in 63 positron emission tomography (PET) studies performed in patients on sorafenib (group 1, n = 20), in a control group (group 2, n = 28) and in patients on sunitinib or vandetanib (group 3, n = 15).Moderate or high and diffuse bowel uptake (grade 4 or 5) was observed in 90% of the PET scans of group 1 versus none in group 2. Only 20% of PET scans in group 3 were scored grade 4. SUVmax values were significantly higher for all colic segments in group 1 than in group 2 (P < 0.0001) or 3 (P < 0.0004). This uptake pattern appeared rapidly (one month) and disappeared after sorafenib withdrawal.ConclusionsFDG uptake is increased in the colon of DTC patients treated by sorafenib.

Report this publication

Statistics

Seen <100 times